Stock events for Kura Oncology, Inc. (KURA)
KURA's stock has increased by 9.00% in the past six months and 16.36% over the past year. The FDA approval of KOMZIFTI on November 13, 2025, was a major milestone, leading to its commercial launch and $2.1 million in net product revenue in five weeks. However, the Q4 2025 earnings report showed a loss of $0.92 per share, missing estimates, and revenues fell short by 41.85%, causing a stock price decrease. Analysts maintain a "Moderate Buy" rating with an average price target of $28.00.
Demand Seasonality affecting Kura Oncology, Inc.’s stock price
Direct demand seasonality is not explicitly indicated for Kura Oncology's products. However, historical stock price data suggests some seasonality in investor interest, with November showing the highest probability of positive returns and April the lowest. The commercial launch of KOMZIFTI indicates market acceptance and a focus on addressing a medical need.
Overview of Kura Oncology, Inc.’s business
Kura Oncology is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, operating in the Biotechnology and Medical industries. Their pipeline includes Ziftomenib (KOMZIFTI), approved for relapsed or refractory NPM1-mutated AML and being investigated for other cancers; Tipifarnib, an FTI for HRAS Mutant Solid Tumors and Chronic Myelomonocytic Leukemia; KO-2806, a next-generation FTI; Darlifarnib, being investigated in combinations across renal cell carcinoma, KRASG12C-mutated non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma; and KO-7246, a next-generation menin inhibitor also being advanced for diabetes and cardiometabolic diseases.
KURA’s Geographic footprint
Kura Oncology is headquartered in San Diego, California, United States.
KURA Corporate Image Assessment
Kura Oncology's brand reputation has been positively impacted by the FDA approval of KOMZIFTI in November 2025, enhancing confidence in its pipeline. The company has received positive feedback on KOMZIFTI's clinical profile, and its patent listing in the FDA's Orange Book extends through July 2044.
Ownership
Kura Oncology has significant institutional ownership, with 265 institutional owners holding 87,021,297 shares as of March 4, 2026, including major holders like BlackRock, Inc. and BVF Inc/il. Insider ownership is relatively low at 2.17%.
